Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.
about
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action.Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adultsDe-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shockProcalcitonin to initiate or discontinue antibiotics in acute respiratory tract infectionsDe-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shockShort-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adultsAdvances in antibiotic therapy in the critically illProcalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unitSepsis: From Pathophysiology to Individualized Patient CareThe importance of serum procalcitonin in diagnosis and treatment of serious bacterial infections and sepsisCommunity-acquired pneumonia: identification and evaluation of nonrespondersStrategies for appropriate antibiotic use in intensive care unitProcalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysisAME evidence series 001-The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospitalEffectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.Tools for outcome prediction in patients with community acquired pneumonia.Advances in Intra-abdominal Sepsis: What Is New?Outcome prediction using clinical scores and biomarkers in patients with presumed severe infection in the emergency department.Antibiotic stewardship in the intensive care unit.Biomarker discovery and development in pediatric critical care medicine.Alveolar pentraxin 3 as an early marker of microbiologically confirmed pneumonia: a threshold-finding prospective observational study.[Procalcitonin as a tool for the assessment of successful therapy of severe sepsis : An analysis using clinical routine data].Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children.Serial Procalcitonin as a Predictor of Bacteremia and Need for Intensive Care Unit Care in Adults With Pneumonia, Including Those With Highest Severity: A Prospective Cohort StudyUsing Procalcitonin to Guide Antibiotic Therapy.Biomarker-guided antibiotic therapy-strengths and limitationsProcalcitonin biomarker kinetics fails to predict treatment response in perioperative abdominal infection with septic shockProcalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases.Predicting outcome in patients with sepsis: new biomarkers for old expectations.Monitoring treatment response in abdominal sepsis with procalcitonin--if only!Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients.ATS Core Curriculum 2014: part I. Adult pulmonary medicine.Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net.Procalcitonin as a prognostic marker for sepsis: a prospective observational study.Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review.Delta neutrophil index as an early marker of disease severity in critically ill patients with sepsis.Biomarkers of acute lung injury: worth their salt?
P2860
Q21195823-15C7467C-634F-458D-9752-41996F31E08DQ24187768-C1D33E37-38E2-478F-BB52-80CC41F1765BQ24198268-E0C6E000-DB3A-441B-A7A3-F49D25CA7646Q24200676-2A1F8335-D206-495D-97AD-5DE40E9A441CQ24235566-74DD7331-4D97-4384-84A6-EFA3AA1ED535Q24236108-E822D8EA-C6CB-4AF8-8511-B31D2CB54AA9Q26749328-376EC7EC-5875-4018-80C5-DDB73641CDF1Q26798459-EB19222E-409D-43AA-96FE-9A9F12C32E78Q26799911-CF4E5897-17B1-49CC-AFAC-7F04DA9553BBQ26827765-CC2EBFA3-0D08-41C4-A158-73455A766303Q27002420-8BD45668-EC27-472A-94C2-F8C38315604AQ27002517-CB7D55FE-774D-4A44-8AE9-171A1B47DD48Q27028085-D57E254E-5D94-49FE-93B1-A86FBE7EB058Q28077765-102B6C45-0A66-406B-95B4-F3F93063A367Q30238953-08494FA9-171D-4773-952D-6B57AC466508Q30240254-262FE6D9-9BEA-4392-ABC6-8160AF3EEEAEQ30279142-761F7665-68FC-4B6C-A247-E94E1A2C6FE5Q30318010-516D3FE3-C75D-4394-BF7F-1B94E373F2A3Q30408712-F46498E5-7753-4299-933E-058328AA0442Q30428168-D88F5D23-9EF0-4874-B6D7-30BC1B471AF4Q30596839-E1619476-0FA1-4576-9866-2999AA0F1130Q31112286-4418F28E-F430-42E6-9100-1E87C2A05CC0Q33557838-1A1E9BF8-8347-4028-A104-1D9F2842F445Q33619503-AAD34C35-BDF0-4FEA-88CC-68E2F07AAB51Q33629533-75875287-3A64-4126-ADB1-9D77A8324EA5Q33629591-2E18E897-55E3-4367-AE04-FE1EC76FBAA9Q33747590-E288804A-2B4E-4464-A193-84835F123447Q33750023-6DBC8D52-41C8-445E-AD1B-E94017387290Q33750355-B5F6FEDB-8DA3-43A0-BEE6-CC22D72F3041Q33752020-B826A8D9-8729-46F8-9DE8-E862D37E40C7Q33752801-43C488A0-6A5F-4A89-834F-B884AE9C4196Q33754533-0D5603AC-6856-4986-B2D8-35A9C30741F5Q33786162-4F50655E-7F95-450E-922D-683EC890A329Q33843533-DDD4B57F-8106-45AB-9766-5752FA3BD27EQ33926563-C47A3919-72BE-4CDF-9819-6FF7B0F4ACA1Q34003193-1515F06B-51FE-4706-9B5E-F2752A489FE0Q34026963-FF24BAAE-198E-4D18-8D01-CF84DD585F12Q34027944-C2088CB3-24E4-4991-A42C-E4B89CA4200AQ34062904-3180D50A-A236-49EE-B564-CD89BBB56B82Q34094906-16500E77-3FCF-4460-85B5-F6B271863136
P2860
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Use of procalcitonin to reduce ...... e randomised controlled trial.
@ast
Use of procalcitonin to reduce ...... e randomised controlled trial.
@en
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units
@nl
type
label
Use of procalcitonin to reduce ...... e randomised controlled trial.
@ast
Use of procalcitonin to reduce ...... e randomised controlled trial.
@en
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units
@nl
prefLabel
Use of procalcitonin to reduce ...... e randomised controlled trial.
@ast
Use of procalcitonin to reduce ...... e randomised controlled trial.
@en
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units
@nl
P2093
P1433
P1476
Use of procalcitonin to reduce ...... e randomised controlled trial.
@en
P2093
Antonio Alvarez
Benoît Veber
Bernard Régnier
Blandine Pasquet
Carole Schwebel
Christophe Cracco
Florence Tubach
Frédérique Schortgen
Jean Chastre
Lila Bouadma
P304
P356
10.1016/S0140-6736(09)61879-1
P407
P577
2010-01-25T00:00:00Z